As Mylan continues to face criticism over price hikes on its EpiPen epinephrine injection, the company agreed to a $465 million settlement with the U.S. Department of Justice and other agencies for overcharging on the EpiPen. Read more
Drug Enforcement Administration (DEA) reduced the amount of almost every Schedule II opiate and opioid medication that may be manufactured in the United States by 25% or more—including a huge cut in this drug. Read more
This month's CE activity, "Rheumatoid arthritis: partnering for optimal care," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat rheumatoid arthritis. Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
FDA approved Amjevita, a biosimilar to Humira, to treat rheumatoid arthritis (RA), psoriatic arthritis, Crohn's disease and other inflammatory conditions. Plus, FDA recently gave the green light to Erelzi, a biosimilar to top-selling Enbrel, also for RA and other inflammatory conditions. Read more
Click to contact the editorial team. Click to contact the sales team.
Part of the
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
